Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Safety, dosimetry and tumor detection ability of 68Ga-NOTA-AE105 - a novel radioligand for uPAR PET imaging: first-in-humans study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Early Postoperative 18F-FET PET/MRI for Pediatric Brain and Spinal Cord Tumors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. PET/CT versus standard imaging for prediction of survival in patients with recurrent head and neck squamous cell carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Relation of cardiac adipose tissue to coronary calcification and myocardial microvascular function in type 1 and type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Surgical Management, Preoperative Tumor Localization, and Histopathology of 80 Patients Operated on for Insulinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: Overexpression of urokinase-type plasminogen activator receptors (uPAR) represents an established biomarker for aggressiveness in most common malignant diseases, including breast (BC), prostate (PC) and urinary bladder cancer (UBC) and is therefore an important target for new cancer therapeutic and diagnostic strategies. In the study, uPAR Positron Emission Tomography (PET) imaging using a (68)Ga-labelled version of the uPAR targeting peptide (AE105) was investigated in a group of patients with BC, PC and UBC. The aim of this first-in-humans, Phase I, clinical trial was to investigate safety and biodistribution in normal tissues and uptake in tumor lesions.

METHODS: Ten patients (6 PC, 2 BC and 2 UBC) received a single intravenous dose of (68)Ga-NOTA-AE105 (154 + 59 MBq; range 48-208 MBq). The biodistribution and radiation dosimetry were assessed by serial PET/CT scans (10 minutes, 1 and 2 hours p.i.). Safety assessment included measurements of vital signs with regular intervals during the imaging sessions and laboratory blood screening tests performed before and after injection. In a subgroup of patients, the in vivo stability of (68)Ga-NOTA-AE105 was determined in collected blood and urine. PET images were visually analyzed for visible tumor uptake of (68)Ga-NOTA-AE105 and Standardized Uptake Values (SUVs) were obtained from tumor lesions by manually drawing volumes of interest (VOIs) in the malignant tissue.

RESULTS: No adverse events or clinically detectable pharmacologic effects were found. The radioligand exhibited good in vivo stability and fast clearance from tissue compartments primarily by renal excretion. The effective dose was 0.015 mSv/MBq leading to a radiation burden of 3 mSv when using the clinical target dose of 200 MBq. In addition, radioligand accumulation was seen in primary tumor lesions as well as in metastases.

CONCLUSION: This first-in-humans, Phase 1 clinical trial demonstrates the safe use and clinical potential of (68)Ga-NOTA-AE105 as a new radioligand for uPAR PET imaging in cancer patients.

OriginalsprogEngelsk
TidsskriftJournal of nuclear medicine : official publication, Society of Nuclear Medicine
Vol/bind58
Udgave nummer3
Sider (fra-til)379-386
ISSN0161-5505
DOI
StatusUdgivet - 2017

ID: 48938129